← All drugs Report issue

azd7451

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Oct 5, 2011 (NCT01468324)

Timeline

2010s

Jan 1, 2011
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Glioblastoma · Phase 1

Mechanism of action

NT-3 growth factor receptorINHIBITOR
NTRK3 inhibitor
- NT-3 growth factor receptor (NTRK3) ↗
Neurotrophic tyrosine kinase receptor type 2INHIBITOR
NTRK2 inhibitor
- BDNF/NT-3 growth factors receptor (NTRK2) ↗
Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
- High affinity nerve growth factor receptor (NTRK1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1

Mol. weight: 382.4 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL3659497 ↗
ChEMBLCHEMBL3545179 ↗

Also known as

azd7451
azd-7451
azd-7451

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01468324	Phase 1	Oct 5, 2011	National Cancer Institute (NCI)

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
National Cancer Institute (NCI)	Government	1	1	1	2011

1 organizations

Page 1 / 1